Molecular Diagnostic of Prostate Cancer Based on Non Invasive Liquid Biopsies
Jack A Schalken, PhD, and E. David Crawford, MD, discuss recent advances in non invasive liquid...
Read More
Video
Imaging of Prostate Cancer Patients Following Definitive Therapy
Dr. Phillip J. Koo, MD, discusses advanced tools such as multi-parametric MRI and PET/CT for prostate cancer imaging, and how they outperform traditional, previously available methods.
Read More
Radiogland Therapy Optimization of PSMA-Targeted Radiation
Scott T. Tagawa, MD, Weill Cornell Medicine, provides an overview of radiogland therapy and...
Read More
An Overview of MRI Guided Biopsies for Prostate Cancer
Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.”
Read More
Novel Hormonal Therapies for Prostate Cancer
Dr. Alan H. Bryce, MD, discusses the newest advances and research in prostate cancer treatments that target androgen receptors, such as BET inhibitors and CYP17 inhibitors, as opposed to chemotherapeutic and radiopharmaceutical approaches.
Read More